Funder
Glaxo Smith Kline/Novartis
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Clinical Neurology,Neurology,Oncology
Reference44 articles.
1. Abrey LE, Christodoulou C (2001) Temozolomide for treating brain metastases. Semin Oncol 28(Supplement 13):34–42. doi: 10.1016/S0093-7754(01)90069-7
2. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL (2002) Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21:6255–6263. doi: 10.1038/sj.onc.1205794
3. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1:85–94
4. Versola M, Burris HA, Jones S, Wilding G, Taylor C, Pandite L, Smith DA, Stead A, Spector NL (2004) Clinical activity of GW572016 in EGF10003 in patients with solid tumors. J Clin Oncol 22:3047–3047. doi: 10.1200/jco.2004.22.14_suppl.3047
5. Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O’Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305–5313. doi: 10.1200/JCO.2005.16.584
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献